Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albiglutide added to metformin versus sitagliptin, glimepiride, or placebo added to metformin in type 2 diabetes
2008-007660-41Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of albiglutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by GSK. Primary endpoint: Change from baseline in HbA1c at Week 104. Started Mar 2009; status: completed.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-007660-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007660-41.